Cargando…

Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more

BACKGROUND: Over the last years, the mean age of subjects with HIV infection and AIDS is increasing. Moreover, some epidemiological and clinical differences between younger and older HIV-infected individuals have been observed. However, since introduction of HAART therapy, there are controversial re...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogueras, MaMercedes, Navarro, Gemma, Antón, Esperança, Sala, Montserrat, Cervantes, Manel, Amengual, MaJosé, Segura, Ferran
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1654166/
https://www.ncbi.nlm.nih.gov/pubmed/17087819
http://dx.doi.org/10.1186/1471-2334-6-159
_version_ 1782131009286832128
author Nogueras, MaMercedes
Navarro, Gemma
Antón, Esperança
Sala, Montserrat
Cervantes, Manel
Amengual, MaJosé
Segura, Ferran
author_facet Nogueras, MaMercedes
Navarro, Gemma
Antón, Esperança
Sala, Montserrat
Cervantes, Manel
Amengual, MaJosé
Segura, Ferran
author_sort Nogueras, MaMercedes
collection PubMed
description BACKGROUND: Over the last years, the mean age of subjects with HIV infection and AIDS is increasing. Moreover, some epidemiological and clinical differences between younger and older HIV-infected individuals have been observed. However, since introduction of HAART therapy, there are controversial results regarding their response to HAART. The aim of the present study is to evaluate epidemiological and clinical features, response to HAART, and survival in elderly HIV-infected patients with regard to younger HIV-infected patients. METHODS: A prospective cohort study (1998–2003) was performed on patients from Sabadell Hospital, in Northeast of Spain. The cohort includes newly attended HIV-infected patients since January 1, 1998. For the purpose of this analysis, data was censured at December 31, 2003. Taking into account age at time of diagnosis, it was considered 36 HIV-positive people aged 50 years or more (Group 1, G1) and 419 HIV-positive people aged 13–40 years (Group 2, G2). Epidemiological, clinical, biological and therapy data are recorded. Statistical analysis was performed using Chi-squared test and Fisher exact test, Mann-Whitney U test, Kaplan-Meier, Log Rank test, and Two-Way ANOVA from random factors. RESULTS: G1 showed higher proportion of men than G2. The most common risk factors in G1 were heterosexual transmission (P = 0.01) and having sex with men or women (P < 0.001). G1 and G2 show parallel profiles through the time regarding immunological response (P = 0.989) and virological response (P = 0.074). However, older people showed lower CD4 cell counts at first clinic visit (P < 0.001) and, eventually, they did not achieve the same counts as G2. G1 presented faster progression to AIDS (P < 0.001) and shorter survival (P < 0.001). CONCLUSION: Older patients have different epidemiological features. Their immunological and virological responses are good. However, older patients do not achieve the same CD4 cell counts likely due to they have lower counts at first clinic visit. Thus, it is essential physicians know older HIV-infected patients features to consider the possibility of HIV infection in these patients with the aim of treatment would not be delayed.
format Text
id pubmed-1654166
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16541662006-11-21 Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more Nogueras, MaMercedes Navarro, Gemma Antón, Esperança Sala, Montserrat Cervantes, Manel Amengual, MaJosé Segura, Ferran BMC Infect Dis Research Article BACKGROUND: Over the last years, the mean age of subjects with HIV infection and AIDS is increasing. Moreover, some epidemiological and clinical differences between younger and older HIV-infected individuals have been observed. However, since introduction of HAART therapy, there are controversial results regarding their response to HAART. The aim of the present study is to evaluate epidemiological and clinical features, response to HAART, and survival in elderly HIV-infected patients with regard to younger HIV-infected patients. METHODS: A prospective cohort study (1998–2003) was performed on patients from Sabadell Hospital, in Northeast of Spain. The cohort includes newly attended HIV-infected patients since January 1, 1998. For the purpose of this analysis, data was censured at December 31, 2003. Taking into account age at time of diagnosis, it was considered 36 HIV-positive people aged 50 years or more (Group 1, G1) and 419 HIV-positive people aged 13–40 years (Group 2, G2). Epidemiological, clinical, biological and therapy data are recorded. Statistical analysis was performed using Chi-squared test and Fisher exact test, Mann-Whitney U test, Kaplan-Meier, Log Rank test, and Two-Way ANOVA from random factors. RESULTS: G1 showed higher proportion of men than G2. The most common risk factors in G1 were heterosexual transmission (P = 0.01) and having sex with men or women (P < 0.001). G1 and G2 show parallel profiles through the time regarding immunological response (P = 0.989) and virological response (P = 0.074). However, older people showed lower CD4 cell counts at first clinic visit (P < 0.001) and, eventually, they did not achieve the same counts as G2. G1 presented faster progression to AIDS (P < 0.001) and shorter survival (P < 0.001). CONCLUSION: Older patients have different epidemiological features. Their immunological and virological responses are good. However, older patients do not achieve the same CD4 cell counts likely due to they have lower counts at first clinic visit. Thus, it is essential physicians know older HIV-infected patients features to consider the possibility of HIV infection in these patients with the aim of treatment would not be delayed. BioMed Central 2006-11-06 /pmc/articles/PMC1654166/ /pubmed/17087819 http://dx.doi.org/10.1186/1471-2334-6-159 Text en Copyright © 2006 Nogueras et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Nogueras, MaMercedes
Navarro, Gemma
Antón, Esperança
Sala, Montserrat
Cervantes, Manel
Amengual, MaJosé
Segura, Ferran
Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
title Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
title_full Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
title_fullStr Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
title_full_unstemmed Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
title_short Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more
title_sort epidemiological and clinical features, response to haart, and survival in hiv-infected patients diagnosed at the age of 50 or more
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1654166/
https://www.ncbi.nlm.nih.gov/pubmed/17087819
http://dx.doi.org/10.1186/1471-2334-6-159
work_keys_str_mv AT noguerasmamercedes epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore
AT navarrogemma epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore
AT antonesperanca epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore
AT salamontserrat epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore
AT cervantesmanel epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore
AT amengualmajose epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore
AT seguraferran epidemiologicalandclinicalfeaturesresponsetohaartandsurvivalinhivinfectedpatientsdiagnosedattheageof50ormore